Jardiance (Empagliflozin)

Empagliflozin blocks the sodium‑glucose co‑transporter‑2 (SGLT2) in the kidney’s proximal tubules, preventing reabsorption of filtered glucose. The excess glucose is expelled in the urine, which lowers plasma glucose levels and produces a modest diuretic effect that contributes to cardiovascular and renal benefits.

The specific dose of Jardiance is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose without medical advice.

The safety of empagliflozin in pregnancy and lactation has not been established. It is generally advised to avoid use during pregnancy and to discontinue breastfeeding while on therapy unless the benefits outweigh potential risks, as decided by a qualified clinician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Jardiance (empagliflozin) shares the class mechanism of glucose excretion with other SGLT2 inhibitors such as canagliflozin and dapagliflozin. Clinical data suggest comparable glycaemic efficacy, but empagliflozin has distinct cardiovascular outcome evidence showing reduction in cardiovascular death in heart‑failure patients.

Jardiance tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect the product from excess moisture and direct sunlight to maintain stability throughout its shelf life.

Jardiance is taken orally, usually once daily in the morning, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed, unless otherwise directed by a healthcare professional.

Serious risks include ketoacidosis (which can occur with modest glucose levels), acute kidney injury, severe dehydration or hypotension, and rare but life‑threatening infections such as Fournier’s gangrene. Patients should be educated to seek immediate medical attention if they experience symptoms like nausea, vomiting, abdominal pain, or unusual fatigue.

Jardiance is contraindicated in patients with severe renal impairment (eGFR below the approved threshold), end‑stage renal disease, or those on dialysis. It should also be avoided in individuals with a known hypersensitivity to empagliflozin or any component of the formulation.